Impact of chronic stress on immunotherapy effectiveness in esophageal cancer patients
Official title: The Effect of Chronic Stress on Efficacy of Immune Checkpoint Inhibitors in Patients With Newly Diagnosed Esophageal Cancer
Run by Second Xiangya Hospital of Central South University · NCT05967910 · Data updated 2026-11-12
This study looks at how ongoing stress might affect the success of immune therapy in people with esophageal cancer who are just starting treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Second Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | May 1, 2023 |
| Main results expected | May 1, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 23, 2024 |
| Trial ID | NCT05967910 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 75 with a pathologically confirmed diagnosis of esophageal cancer who have not yet received systemic treatment.
✕Probably not a fit
Patients with other concurrent malignancies or those with significant mental health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates how chronic stress affects the efficacy of immune checkpoint inhibitors (ICIs) in patients diagnosed with esophageal cancer. It aims to understand the relationship between psychological stress and tumor progression, particularly focusing on the hormonal responses triggered by stress. By analyzing tumor tissue samples and patient health indicators, the study seeks to clarify the potential impact of chronic stress on treatment outcomes for newly diagnosed patients who have not yet received systemic anti-tumor therapy.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for esophageal cancer patients by addressing the role of stress in treatment efficacy.
How similar studies have gone: While there is evidence from animal models suggesting stress impacts tumor behavior, the specific effects on esophageal cancer and immunotherapy efficacy remain largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years and ≤ 75 years old 2. Pathologically diagnosed as esophageal cancer 3. Patient tumor tissue samples can be obtained 4. At least one measurable lesion can be evaluated according to the RECIST 1.1 standard 5. As a newly treated patient, they have not received systematic anti-tumor treatment for locally advanced or metastatic chest tumors 6. There is no obvious abnormality in the electrocardiogram and no obvious cardiac dysfunction 7. Hematology and liver and kidney function indicators meet the requirements Exclusion Criteria: 1. Merge with other malignant tumors 2. Long term use of hormones or immunosuppressants 3. Concomitant acute or chronic mental illness 4. Patients who have been taking drugs that can alter the activity of the sympathetic nervous system for a long time or are currently taking them 5. Other malignant diseases that require systematic treatment 6. Patients who have undergone other clinical drug experiments before 7. Patients with symptomatic brain metastases
Where it's running
-
Department of Oncology, The Second Xiangya Hospital, Central South University
Changsha, Hunan, China Recruiting
Study contacts
- Study coordinator: Fang Wu, MD.PhD
- Email: wufang4461@csu.edu.cn
- Phone: +86 135744858332
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nimotuzumab with Chemoradiotherapy for Esophageal Cancer
This study is testing if a combination of a new antibody treatment, chemotherapy, and radiation can help older or malnourished patients with advanced esophageal cancer feel better and improve their chances of recovery.
-
Combining immunotherapy and chemoradiotherapy for esophageal cancer treatment
This study is testing if combining a new immunotherapy drug with traditional chemoradiotherapy can help people with advanced esophageal cancer have better treatment results.
-
Using sintilimab after chemoradiotherapy for elderly patients with esophageal cancer
This study is testing if adding a new treatment called sintilimab after chemotherapy and radiation can help older patients with esophageal cancer live longer and healthier.
-
Nimotuzumab with Chemoradiotherapy for Unresectable Esophageal Cancer
This study is testing if adding a new drug called nimotuzumab to chemotherapy and radiation can help patients with advanced esophageal cancer who haven't improved with earlier treatments.
-
Neoadjuvant treatments for esophageal cancer
This study is testing different combinations of treatments for people with esophageal cancer to see if they can improve outcomes compared to just having surgery.
-
Combining chemotherapy and immunotherapy for esophageal cancer treatment
This study is testing if combining immunotherapy with chemotherapy can help improve survival for patients with esophageal cancer who had surgery but are at high risk of their cancer coming back.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.